key: cord-0974395-ovqgate3
authors: Pani, Arianna; Cento, Valeria; Vismara, Chiara; Campisi, Daniela; Di Ruscio, Federica; Romandini, Alessandra; Senatore, Michele; Schenardi, Paolo Andrea; Gagliardi, Oscar Matteo; Giroldi, Simona; Zoppini, Laura; Moreno, Mauro; Corradin, Matteo; Epis, Oscar Massimiliano; Ughi, Nicola; Cuppari, Irene; Crocchiolo, Roberto; Merli, Marco; Bosio, Marco; Rossini, Silvano; Puoti, Massimo; Scaglione, Francesco
title: Antibody response to BNT162b vaccine is almost universal in health care workers. Results from the RENAISSANCE study: REsponse to BNT162b2 COVID-19 vacciNe - short And long term Immune reSponSe evAluatioN in healthCare workErs
date: 2021-08-30
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2021.08.013
sha: b0bdbe839f56e8068a66e4c4d54ae9f21dabdf2e
doc_id: 974395
cord_uid: ovqgate3

Objective To evaluate the SARS-CoV-2 anti-spike IgG antibodies production after the vaccination with BNT162b2 and the protection from symptomatic breakthrough infections in healthcare workers. Patients and methods This prospective observational study (RENAISSANCE) had as primary endpoint the evaluation of serologic response to BNT162b2 14-days after second dose. SARS-CoV-2 anti-spike IgG antibodies were evaluated with LIAISON® SARS-CoV-2 TrimericS IgG assay, able to detect presence of both binding and neutralizing antibodies for trimeric Spike glycoprotein. Subjects were recruited from February 1, 2021 to February 22, 2021. Occurrence of vaccine-breakthrough infections was assessed by RT-PCR on symptomatic/contact cases, up to June 6, 2021. Results Out of 2569 staff only were 4 non-responders (0.16%, 95%CI:0.04%-0.41%). All 4 non-responders were severely immunosuppressed and on treatment with mycophenolate mofetil/mycophenolic acid. At 14-days since 2° dose, the 67.5% of staff had anti-S IgG titers ≥2000 BAU/mL, 19.2% between 1500- 2000 BAU/ml, 9.8% between 1000-1500 BAU/ml, and 3.4% ≤1000 BAU/ml. Females had a higher probability of having higher titers than males (64.5% [1044/1618] vs. 58.3% [410/703]; p=0.005). This was confirmed after adjusting for age group (OR [95%CI]: 1.275 [1.062-1.531]; p=0.009). Four months after the end of vaccination program, only 13 subjects (0.26%) had experienced a breakthrough SARS-CoV-2 infection, including 1 non-responder. This subject was the only requiring hospitalization for severe COVID-19. Conclusion Vaccination campaign among healthcare workers at the ASST GOM Niguarda has resulted in a significative serologic response, and reduction of incident COVID-19 cases. Yet, the lack of protection should not be overlooked in immunocompromised subjects.

On December 21, 2020 the European Commission granted the first European conditional marketing authorization (CMA) for the active immunisation of adults aged over 16 years with the BNT162b2 vaccine (Pfizer-Biontech). This approval was the result of an unprecedented effort undertaken by companies, regulatory authorities and academia, that enabled the development of vaccines in as short as 10 months. Soon after the approval, vaccination campaigns for health workers across USA and Europe began immediately. As of May 10, 2021, the CDC COVID-19 Vaccine tracker counts a total of 259.716.989 dose administered in the United States (https://covid.cdc.gov/covid-datatracker/#vaccinations).

BNT162b2 is a vaccine containing a nucleoside-modified messanger RNA (mRNA) able to encode for the full-length SARS-CoV2 Spike (S) glycoprotein, enclosed within a lipid nanoparticle (LNP) shell with the role of protecting it from degradation, and thus promoting delivery to the target cell. In the phase III trial that led to market approval, the BNT162b2 vaccine has demonstrated a 95% clinical efficacy in preventing COVID-19 (95% CI 90.3-97.6; >0.9999 posterior probability of true vaccine efficacy >30%) [1] .

The BNT162b2 immunogenicity had been evaluated during previous, smaller, phase I-II trials. These demonstrated that, for all doses tested, anti-S IgG antibody production was detectable at 21 days after the first dose, with a boost effect from the second dose, leading to a peak antibody response within the next 7 days. 50% neutralization titer was found to peak at 7 days after the second dose in the population between 18-55 years of age, but in the population between 65-85, the peak of production reached 14 days after the second dose. [2] . The rapid approval of COVID-19 vaccines, dictated by the impending need, has previously led to a poor representation, in clinical trials, of variability in background and clinical and demographic conditions of the population, to which clinical practice studies are called to respond. BNT162b2 clinical trials systematically excluded immunosuppressed individuals and those with history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention. In addition, the immunogenicity of the BNT162b2 at the approved dose of 30 μg has been evaluated only in 12 subjects in the age group of 18-55 years, and 12 in the age group 65-85 years [2] . Data on large populations, more representative of the general population in individual epidemiological settings, are therefore urgently needed.

The RENAISSANCE study is an observational study aimed to evaluate the serologic response to the BNT162b2 COVID-19 vaccine in the staff of the main COVID-19 reference hospital of Milan, Italy, at multiple time-point after a hospital-wide vaccination campaign. Here we report the results the J o u r n a l P r e -p r o o f pag. 6 efficacy of BNT162b2 vaccine in promoting anti-Spike antibody production and confer protection against symptomatic and severe forms of COVID-19 at day-14 after second vaccine dose, in over 2,500 healthcare workers.

RENAISSANCE is a prospective, observational, population-based study of healthcare workers of ASST Grande Ospedale Metropolitano Niguarda in Milan, Italy. All staff with no history of previous laboratory-confirmed COVID-19, and who completed the BNT162b2 vaccine schedule, were eligible for inclusion. BNT162b2 has been administered in two doses of 30 g, as described in the summary of product characteristics [3] . Primary endpoint of the study was the evaluation of IgG antibodies against S glycoprotein produced 14 days after the second dose of BNT162b2. Secondary endpoint was the evaluation of the clinical efficacy of vaccination, testified by the protection from symptomatic COVID-19. No systematic RT-PCR screening was established, but RT-PCR was provided to all symptomatic subjects and to those who reported direct contact to COVID-19 cases. Anti-Nucleocapsid (N) total Ig seropositivity at day-14 after second vaccine dose was used to discriminate staff who had a history of unrecognized contact with SARS-CoV-2.

During the clinical visit at recruitment appointment, each participant received a self-administered, standardized questionnaire covering major chronic health conditions, sociodemographic characteristics, occupational histories, and, for women, reproductive history, to be compiled on a volunteer basis. A survey for the self-report of adverse events was also administered at the time of enrollment.

The study was approved by the local ethics committee Milano Area 3, by the national ethics committees for COVID-19 studies Lazzaro Spallanzani -IRCCS, and by AIFA. All participants provided signed informed consent.

All eligible hospital staff were invited to participate in the study by email, which provided the indication for an appointment for a visit.

Two samples of 3 mL of peripheral venous blood were taken from each participant. Blood samples were stored at room-temperature for 2-4 hours upon collection, and then centrifuged to separate plasma, that was conserved at +4°C until processing, that occurred within 1-5 days.

Full study protocol is available online (in Italian). Laboratory methods SARS-CoV-2 anti-spike IgG antibodies production was evaluated by the LIAISON® SARS-CoV-2 TrimericS IgG assay (DiaSorin S.p.A., Saluggia, Italy), a second-generation standardized, automated chemiluminescent (CLIA) assay able to detect the presence of antibodies for trimeric Spike glycoprotein, including those directed against the receptor-binding domain. The DiaSorin test is quantitative, with optimal sensitivity and specificity for IgG detection within the time-interval useful for the study (98.7% and 99.5%, respectively), and consistently correlated with neutralizing activity [4] . Results are provided as binding arbitrary units (BAU) per mL [4] . According to manufacturer's indications, values <33.8 BAU/mL were reported as negative.

Total Anti-N Ig antibodies production was assessed by an electrochemiluminescence immunoassay A multivariable logistic regression on BAU/mL>2000 (yes/no) was implemented considering age group and sex as independent variables. Adjusted Odd Ratio and its CI 95% were reported. Stata 16.1 was used for all analyses.

The study was funded through divisional funds from the Clinical Chemistry and Microbiology, Infectious Diseases and Transfusion Medicine Units of ASST GOM Niguarda. ASST GOM Niguarda provided support from the nursing staff and facilities to conduct the study. All authors confirm that they had full access to all the data in the study and accept responsibility to submit for publication. Anti-N Ab screening revealed an anti-N seroprevalence of 6.3% (95% CI: 5.4%-7.4%), as 163 subjects with no previous history of laboratory-confirmed COVID-19 were found to be anti-N Ig positive, suggesting a history of unrecognized contact with SARS-CoV-2. Table 1 describes the demographic characteristics and job titles of the total population and subpopulations of anti-N positive and negative staff.

Overall, the median (IQR) age was 48 (36-56) years, and 787 (30.6%) were aged ≥55 years. Female sex accounted for 69.6% of population (n=1789); median (IQR) BMI was 23 (21) (22) (23) (24) (25) (26) (27) . Most of the staff who joined the study were nurses (32.4%, n=832), and medical doctors (23.7%, N=608).

Out of 2569 staff tested, only 4 resulted to be anti-spike antibodies negative (0.16% prevalence;

95% CI: 0.04%-0.40%) and were thus classified as non-responders. All of them were anti-N IgG negative, immunocompromised and assuming mycophenolate ( Table 2) A minority of vaccinated subjects (n/N=87/2569, 3.4%) had detectable anti-spike IgG but ≤1000 BAU/ml, while 67.5% (n/N=1733/2569) had titers ≥2000 BAU/mL. In addition, the 9.8% (n/N=251/2569) had anti-spike IgG titers between 1000 and 1500 BAU/ml, and the 19.2% (n/N=494/2569) had titers between 1500 and 2000 BAU/ml. As reported in Figure 2 In anti-N negative staff, sex and age were two determinant characteristics for anti-Spike IgG response (Figure 2, P= .02) (Supplemental Figure) .

A subgroup of 1886 staff volunteered to complete a survey on concurrent comorbidities, and the 22.7% of them (n/N=428/1886) declared to be affected by at least one disease (Supplemental Table   1 ). The most frequently reported were cardiovascular diseases (10.8%, n/N=204/1886) and endocrine system diseases (5.5%, n/N=103/1886). The 3.6% of subjects (n/N=68/1886) declared to suffer from an autoimmune disease, while 1.4% was immunosuppressed (n/N=27/1886).

The concomitant immunosuppression at the time of vaccination was significantly associated with a different distribution of anti-Spike IgG titers (Supplemental Table 2 Table 2 ). Their nasopharyngeal SARS-CoV-2 genomic RNA load ranged from 1,195 to >10 7 copies/mL, as assessed trough droplet-digital PCR [6] .

Notably the only subject who developed a symptomatic, moderate-to-severe infection requiring hospitalization was one of the 4 non-responders enrolled in our study. Among the 7 infected subjects enrolled in the study who developed a positive anti-S IgG titer, 2 subjects had titers between 1000-1500 BAU/mL, 2 had titers between 1500-2000 BAU/mL, and 3 had titers >2000 BAU/mL. Despite the small numbers, the distribution of anti-S titers at 14-days was significantly different between those who later-on became infected with SARS-CoV-2 and the rest of the population (p=0.008 by Fisher exact test; Figure 2, Our results are in agreement with emerging data from other health-care settings, that documented a consistent immunological response to BNT162b2 vaccination [7] [8] [9] , and rare occurrence of vaccine breakthrough infections [10] [11] [12] [13] [14] [15] .Indeed, similar-sized studies in Israel, Spain and California reported only sporadic cases of asymptomatic or paucisymptomatic breakthrough infections among fullyvaccinated subjects tested >14-days after second dose of an mRNA vaccine [12, 14, 15] .

During vaccine roll-out and follow-up, Milan has witnessed an alarming increase in viral variants.

The B.1.1.7 has been the dominant variant of concern (VOC) [16] circulating in Lombardy region since February 2021 (when our study was initiated), and progressively increased its prevalence from 64% to 89.1% in May 18, 2021 (last epidemiological update available) [17] . The second most prevalent VOC in Lombardy is B.1.617 (Indian variant), with 2.5% prevalence, followed by P. (low) breakthrough infection rate, as the estimated effectiveness of BNT162b2 vaccine against the B.1.1.7 VOC is 89.5% at ≥14 days after the second dose [18] . In vitro data support the preservation of neutralizing activity by antibodies developed with BNT162b2 vaccine against B.1.1.7 [19, 20] , while pointing towards a possible reduction of effectiveness against B.1.351 (South African) [20, 21] and P.1 (Brazilian) [22] VOCs. Reassuringly, emerging data on the new B.1.617 VOC suggest that the reduction of BNT162b2 efficacy is likely to be modest [23, 24] . While assessment of viral lineages in our vaccine breakthrough infection is ongoing, careful surveillance is mandatory, especially in the light of the reduced neutralizing activity of emerging VOCs.

The few cases of breakthrough infections we registered were "enriched" by patients with lower anti-S IgG titers at 14-day follow-up, including 1 out of the 4 non-responders. This latter patient was the only one requiring hospital admission for severe pneumonia. Although we still lack of solid data to define an antibody titer "fully protective", also due to heterogeneity and continuous evolution of commercial assay, it is important to note that all the four subjects who did not respond to vaccination share an important immunosuppression, a condition that was associated with lower response rates to BNT162b2 vaccination in our study. Immunosuppressed or immunocompromised subjects have been excluded for protocol from all trials on COVID-19 vaccine approved to date [1, [25] [26] [27] excluding Ad26.COV2.S (NCT04505722). Despite this lack of evidence and because of the high-risk profile, this population has been included in the vaccination plans of every country.

Notably, all our 4 non-responders were assuming high doses of immunosuppressive drugs, including mycophenolate mofetil (MMF). MMF a mycophenolic acid (MPA) prodrug, depletes guanosine nucleotides through the inhibition of inosine-5'-monophosphate dehydrogenase (IMPDH), acting preferentially on T-and B-lymphocytes [1] . IMPDH is the rate-limiting enzyme in the de novo synthesis of guanosine nucleotides, and T-and B-lymphocytes depend on this pathway more than other cell types. MPA is also a more potent inhibitor of the type II isoform of IMPDH, which is expressed in activated lymphocytes, than of the type I isoform of IMPDH, which is expressed in most other cell types [2] . Therefore, MPA exerts a more potent cytostatic effect on lymphocytes than on other cell types. This is the main mechanism by which MPA suppresses the cell-mediated immune response and antibody formation. However 2 patients were assuming also prednisone and two cyclosporine [28] which cause T cell proliferation inhibition and decrease in the total T cell number [29] . Boyarsky et al. [30] This reminds us that the population of immunocompromised patients, which also includes patients with autoimmune diseases receiving immunosuppressive drugs, needs special attention. Collecting data on whether immunosuppressive therapies may, or may not, impact the response to SARS-CoV2 vaccines is of vital importance, as this is the only way to evaluated whether there is a clinical necessity to establish protocols for the suspension (when possible) of immunosuppressive therapies in proximity of vaccination. Waiting for further data, it appears extremely clear that immunocompromised or immunosuppressed patients should be monitored by assessing the anti-S IgG antibody titer after vaccination.

Age and sex also contributed to the immunological response to vaccination in our study, consistently with previous literature [31, 32] and clinical trials [1] . Subjects older than 55 years were less frequently able to develop antibody titers >2000 BAU/ml compared to younger population, even though only 5.2% of them had Anti-S IgG titers <1000 BAU/mL. In addition, regardless of age, we observed a significantly higher probability for woman of having the highest anti-trimeric S IgG titer than males. Although the positive influence of estrogens on the immune response is known [33, 34] , no impact of estroprogestinic therapy on the response to vaccination has been observed.

According to the Centers for Disease Control and Prevention (CDC) COVID-19 vaccine safety update [35] on the first 13.7 million Covid-19 vaccine doses administered in the US, 79.1% of the adverse effects had been experienced by women, while only the 61.2% of the vaccines had been received by a woman. As recently highlighted by Vijayasingham et al. sex-disaggregated analysis [36] and reporting have been neglected also in COVID-19 vaccines clinical trials. Given the remarkable diversity in the immune response between men and women, data regarding serological response and adverse events in woman should be reported, in order to precisely understand sex-specific characteristics of response to vaccines and also to hypothesize a sex-differentiated dosing regimen.

Of note, although patients with known history of exposure to SARS-CoV2 were excluded by protocol, we included in our analysis those subjects who had never been diagnosed with infection, but who tested positive for anti-nucleocapsid antibodies at the time of execution of our serological evaluation. Among these, we recorded a higher prevalence of subjects with antibody titer above 

Will individual participant data be available (including data dictionaries)?

Yes What data in particular will be shared?

Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)

What other documents will be available? Study protocol (in Italian)

When will data be available (start and end dates)?

Immediately following publication; no end date With whom? Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose and who provide a methodologically sound proposal

For what types of analyses? To achieve aims in the approved proposal

By what mechanism will data be made available?

Proposals should be directed to the corresponding author; to gain access, data requestors will need to sign a data access agreement 

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

A Via Crescentino SNC SV-I: LIAISON® SARS-CoV-2 TrimericS IgG assay -Product Information

Diagnostics R: Elecsys® Anti-SARS-CoV-2 Factsheet

Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients

Piano Mortari E et al: Induction of immune response after SARS-CoV-2 mRNA BNT162b2 vaccination in healthcare workers

Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers

Antibody responses to BNT162b2 mRNA COVID-19 vaccine in 2,015 healthcare workers ina single tertiary referral hospital in Japan

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Vaccine Breakthrough Infections with SARS-CoV-2 Variants. The New England journal of medicine 2021

SARS-CoV-2 Infection after Vaccination in Health Care Workers in California

Post-vaccination SARS-CoV-2 infections and incidence of presumptive B.1.427/B.1.429 variant among healthcare personnel at a northern California academic medical center

SARS-CoV-2 infection in properly vaccinated healthcare workers

Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers

Preventio CfDCa: SARS-CoV-2 Variant Classifications and Definitions

Prevalenza e distribuzione delle varianti del virus SARS-CoV-2 di interesse per la sanità pubblica in Italia

National Study Group for C-V: Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. The New England journal of medicine

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Cyclosporine and the immune response: basic aspects

Prednisone and T-cell subpopulations

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

The effect of ageing of the immune system on vaccination responses

The Gender Impact Assessment among Healthcare Workers in the SARS-CoV-2 Vaccination-An Analysis of Serological Response and Side Effects

Sex-based differences in immune function and responses to vaccination

Sex and Gender Differences in the Outcomes of Vaccination over the Life Course

Control CfD: Vaccine Adverse Event Reporting System (VAERS)

Initiative C-RA-s: Sex-disaggregated data in COVID-19 vaccine trials

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2